HF 0699

Drug Profile

HF 0699

Alternative Names: L-Arg-3,4; L-Arginyl-3,4-Spermidine

Latest Information Update: 07 Apr 2006

Price : $50

At a glance

  • Originator University of Southampton
  • Class Amino acids; Neuroprotectants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Stroke

Most Recent Events

  • 07 Apr 2006 No development reported - Preclinical for Stroke in United Kingdom (unspecified route)
  • 09 Dec 2003 A preclinical study has been added to the adverse events and Neurological disorders pharmacodynamics sections
  • 24 Nov 2003 Preclinical trials in Stroke in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top